ChroMedX Engages Witteveen as European Business Development Advisor

Toronto, Ontario / ACCESSWIRE / October 16, 2014 / ChroMedX Corp. (CSE: CHX) (the "Company") is pleased to announce the engagement of European based Business Development Consultant Marco Witteveen to assist the Company in the international commercialization of its innovative point of care and in-vitro diagnostics technologies.

Marco Witteveen received his B.A.Sc. in International Business and M.A.Sc degree in Strategic Sales Management in Utrecht, the Netherlands. He has over 20 years experience in the healthcare industry beginning with Synthes/Sulzer, a Swiss orthopedic and traumatology implant company, in the Netherlands where he held positions in Sales Management. As a National Sales Director at Abbott Laboratories he was responsible for both the Hospital -and the Medical Nutrition Division and lead the Sales and Marketing Excellence project to drive efficiency and effectiveness in the organization. For the last 9 years he held Global Executive Sales -and Marketing positions at Alere Health Inc., the global leader in rapid Point of Care diagnostics, were he worked on new market development, product commercialization, strategic planning and cross-functional leadership in Sales, Marketing, Clinical, Regulatory, Finance and R&D.

Mr. Witteveen will assist the Company by pursuing development/commercialization opportunities for the Company's blood analysis technologies in the European market by forging strategic relationships with global healthcare industry leaders and distributors.

"We are very pleased to have Mr. Witteveen join the ChroMedX team. His in-depth knowledge of the Point of Care industry and particularly the European landscape will be a great addition to our commercialization efforts. We look forward to utilizing Mr. Witteveen's experience and network to allow us to aggressively expand our operations in the global marketplace", said Dr. Wayne Maddever ChroMedX CEO

ChroMedX on Video

Dr. Wayne Maddever discusses ChroMedX's patented HemoPalm Blood Analysis Technology

If you cannot view the video above, please visit:
https://www.youtube.com/watch?v=izm4G_ktA4c

About ChroMedX Corp.

ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued US and pending international patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.:
Website: www.chromedx.com
Facebook: facebook.com/chromedxcorp
Twitter: www.twitter.com/Chromedxcorp

Contact
Wayne Maddever
President, CEO & Director
647-872-9982

W. Clark Kent
Corporate Development
647-519-2646
ckent@chromedx.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedar.com

The security symbol, MNLIF, is part of the OTC Grey Market, where Monarch does not provide any reports and has no obligation to do so. There are no market makers under this symbol of this security. It is not listed, traded or quoted on any U.S. stock exchange or the OTC Markets. Trades in grey market stocks are reported by broker-dealers to their Self Regulatory Organization (SRO) and the SRO distributes the trade data to market data vendors and financial websites so investors can track price and volume. Since grey market securities are not traded or quoted on an exchange or interdealer quotation system, investor's bids and offers are not collected in a central spot so market transparency is diminished and best execution of orders is difficult.

SOURCE: ChroMedX Corp.